CN116370551A - 一种降高低密度脂蛋白和高甘油三酯的植物提取液 - Google Patents
一种降高低密度脂蛋白和高甘油三酯的植物提取液 Download PDFInfo
- Publication number
- CN116370551A CN116370551A CN202310388524.1A CN202310388524A CN116370551A CN 116370551 A CN116370551 A CN 116370551A CN 202310388524 A CN202310388524 A CN 202310388524A CN 116370551 A CN116370551 A CN 116370551A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- low density
- density lipoprotein
- jianghua
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001603 reducing effect Effects 0.000 title claims abstract description 50
- 108010007622 LDL Lipoproteins Proteins 0.000 title claims abstract description 39
- 102000007330 LDL Lipoproteins Human genes 0.000 title claims abstract description 39
- 108010010234 HDL Lipoproteins Proteins 0.000 title claims abstract description 34
- 102000015779 HDL Lipoproteins Human genes 0.000 title claims abstract description 34
- 239000000419 plant extract Substances 0.000 title claims abstract description 34
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 117
- 244000269722 Thea sinensis Species 0.000 claims abstract description 52
- 239000002994 raw material Substances 0.000 claims abstract description 48
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 33
- 244000197580 Poria cocos Species 0.000 claims abstract description 33
- 235000006533 astragalus Nutrition 0.000 claims abstract description 26
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 25
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- 239000001301 oxygen Substances 0.000 claims abstract description 16
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 15
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 12
- 238000003809 water extraction Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241001092040 Crataegus Species 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 16
- 235000020717 hawthorn extract Nutrition 0.000 claims description 16
- 238000006213 oxygenation reaction Methods 0.000 claims description 10
- 235000006751 Platycodon Nutrition 0.000 claims description 9
- 229930189914 platycodon Natural products 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 235000019206 astragalus extract Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 33
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 10
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 42
- 235000013616 tea Nutrition 0.000 description 39
- 240000003582 Platycodon grandiflorus Species 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229930189407 platycodin Natural products 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 4
- 229940047169 astragalus root extract Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- LAWPHHZXTUPSDG-UHFFFAOYSA-N Astragaloside I Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C)C1OC(=O)C LAWPHHZXTUPSDG-UHFFFAOYSA-N 0.000 description 3
- KXHCYYSIAXMSPA-UHFFFAOYSA-N Astragaloside-I Chemical compound CC(=O)OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 KXHCYYSIAXMSPA-UHFFFAOYSA-N 0.000 description 3
- LVBLYMQWWGLBRE-UHFFFAOYSA-N Astragaloside-II Chemical compound CC(=O)OC1C(C(COC1OC2CCC34CC35CCC6(C(C(CC6(C5CC(C4C2)OC7C(C(C(C(O7)CO)O)O)O)C)O)C8(CCC(O8)C(C)(C)O)C)C)O)O LVBLYMQWWGLBRE-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241000209035 Ilex Species 0.000 description 3
- 235000003332 Ilex aquifolium Nutrition 0.000 description 3
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 3
- 235000002294 Ilex volkensiana Nutrition 0.000 description 3
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 3
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- -1 platycodin Chemical class 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JLKGXASMCRAVAK-UHFFFAOYSA-N Astragaloside-II Natural products CC(=O)OC1C(O)C(O)COC1OC2CCC34CC35CCC6(C)C(C)(CCC6(O)C7(C)CCC(O7)C(C)(C)O)C5CC(OC8OC(CO)C(O)C(O)C8O)C4C2(C)C JLKGXASMCRAVAK-UHFFFAOYSA-N 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 235000014493 Crataegus Nutrition 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- DJHCVWLJAINILQ-UHFFFAOYSA-N Cyclosieversioside D Natural products CC(=O)OC1C(O)C(O)COC1OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O DJHCVWLJAINILQ-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- HJCCJZGOBHFQSX-UHFFFAOYSA-N cyclosieversioside B Natural products CC(CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1O)C2C(CC3(C)C4CC(O)C5C(C)(C)C(CCC56CC46CCC23C)OC7OCC(O)C(O)C7O)OC8OC(CO)C(O)C(O)C8O HJCCJZGOBHFQSX-UHFFFAOYSA-N 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 108010068815 steroid hormone 7-alpha-hydroxylase Proteins 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- NSRJSISNDPOJOP-BBRMVZONSA-N (-)-medicarpin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C(OC)C=C1O2 NSRJSISNDPOJOP-BBRMVZONSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- QGDOQULISIQFHQ-UHFFFAOYSA-N 1,3,7,9-tetramethyluric acid Chemical class CN1C(=O)N(C)C(=O)C2=C1N(C)C(=O)N2C QGDOQULISIQFHQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GVBHCMNXRKOJRH-UHFFFAOYSA-N 2,4,5,6-tetrachloropyrimidine Chemical compound ClC1=NC(Cl)=C(Cl)C(Cl)=N1 GVBHCMNXRKOJRH-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 101000659079 Homo sapiens Synaptoporin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- SRPWHXRCOLBHSL-UHFFFAOYSA-N astragaloside III Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OCC(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C7C(C)(C)C(O)CCC78CC48CCC23C SRPWHXRCOLBHSL-UHFFFAOYSA-N 0.000 description 1
- QMNWISYXSJWHRY-XZFBGSIGSA-N astragaloside a Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4C([C@@H](O)C(O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XZFBGSIGSA-N 0.000 description 1
- FVFSMBDVZVUETN-PTCJJXKDSA-N astragalosideiii Chemical compound O1[C@H](C(C)(O)C)CC[C@@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O FVFSMBDVZVUETN-PTCJJXKDSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 102000054423 human SYNPR Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000000396 limonene group Chemical group 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降高低密度脂蛋白和高甘油三酯的植物提取液及其制备方法,属于中药技术领域。该植物提取液是以具有药食同源的原料进行组配,进而获得一种能够同时降高低密度脂蛋白和高甘油三酯的产品。该产品兼具有效性和安全性。该植物提取液的制备方法中,通过水提将山楂、桔梗、茯苓、陈皮和黄芪中的具有降血脂的有效成分析出后,再对江华苦茶原料在一定温度下,导入氧气使提取液中有效成分含氧量提高,进一步保证了江华苦茶原料中有效成分发挥更大的功效。上述各原料提取液混合后,共奏兼具降高低密度脂蛋白和高甘油三酯的作用。
Description
技术领域
本发明属于中药技术领域,具体涉及一种降高低密度脂蛋白和高甘油三酯的植物提取液及其制备方法。
背景技术
高血脂症指人体内胆固醇或甘油三酯的含量增高。胆固醇以低密度脂蛋白的形式存在于血液中,沉积于血管壁上与增生的纤维组织形成斑块,从而导致动脉血管内壁增厚,弹性降低,血压增高,发生动脉粥样硬化。
甘油三酯参与人体内的能量代谢过程,低密度脂蛋白参与合成细胞浆膜、类固醇激素和胆汁酸等。大量研究表明血浆低密度脂蛋白和甘油三酯水平的升高是肥胖、高血压、糖尿病、动脉粥样硬化等多种代谢性疾病的主要危险因素之一。因此,能够有效降低血脂对防治心脑血管病及多种代谢性疾病具有积极的临床价值和重要意义。
目前现代临床药物治疗主要分为:降低总胆固醇和低密度脂蛋白的他汀类药物、抑制肠道胆固醇吸收的依折麦布、降低胆固醇合成同时促进胆固醇分解的普罗布考等。但是,他汀类药物可能出现头痛、腹泻、肝功能异常等不良反应,依折麦布可能出现头痛、腹痛、腹泻等不良反应且孕妇及哺乳期妇女禁用,普罗布考可引起胃肠道反应及心律失常等不良反应。降低甘油三酯的药物主要包括:贝特类、烟酸类及鱼油类。其中贝特类的主要不良反应有头痛、发力、眩晕及肠道不良反应,肝肾功能不全患者、儿童、孕妇等禁用。烟酸类在临床中已较少使用,鱼油类安全性较高但临床疗效较弱。上述现有常用的药物均具有功能单一且副作用明显的缺点。
发明内容
本发明的目的在于提供一种降高低密度脂蛋白和高甘油三酯的植物提取液,该植物提取液是以具有药食同源的原料进行组配,进而获得一种能够同时降高低密度脂蛋白和高甘油三酯的产品。该产品兼具有效性和安全性。
江华苦茶的特性:1、在江华县境内;2、总多酚类物质“茶多酚“较其它茶类高20%以上,因止苦味较重。本专利对提取液进行氧化,是让茶叶中苦的成分“儿茶素”能过强行发酵转化成茶褐素,去除苦味。3、江华苦茶中含有较多的“四甲基尿酸生物碱”;总生物碱较普通茶也高20%左右,也是茶叶苦的原因之一。普通茶叶不含或含量低,普通茶叶70%以上是咖啡碱。在氧化时,茶叶提取液中的生物碱与有机酸会有一定程度中和,黑茶是发酵茶,在发酵时中和了,因止安化黑茶养胃而不伤胃;安神而不剌激神经。
本发明通过以下技术方案实现:
一种降高低密度脂蛋白和高甘油三酯的植物提取液,所述植物提取液主要由以下质量份数的原料制备得到:
山楂提取液10-40份,桔梗提取液8-30份,茯苓提取液8-30份,陈皮提取液5-30份,黄芪提取液5-30份和江华苦茶提取液5-30份。
作为优选地,所述植物提取液主要由以下质量份数的原料制备得到:
山楂提取液20-30份,桔梗提取液15-20份,茯苓提取液15-20份,陈皮提取液10-20份,黄芪提取液10-20份和江华苦茶提取液份10-20份。
作为优选地,所述植物提取液主要由以下质量份数的原料制备得到:
山楂提取液23份,桔梗提取液16份,茯苓提取液16份,陈皮提取液13份,黄芪提取液13份和江华苦茶提取液13份。
作为优选地,所述植物提取液主要由以下质量份数的原料制备得到:
山楂提取液26份,桔梗提取液18份,茯苓提取液18份,陈皮提取液15份,黄芪提取液15份和江华苦茶提取液15份。
山楂,中药名。为蔷薇科山楂属植物山里红Crataegus pinnatiidaBge.var.major N.E.Br.或山楂Crataegus pinnatifida Bge.的干燥成熟果实。具有消食化积,行气散瘀的功效。主治饮食积滞,泻痢腹痛,疝气痛,瘀阻胸腹痛,痛经。味酸、甘,性微温;归脾、胃、肝经。化学成分:山楂含黄酮类、三萜皂苷类(熊果酸、齐墩果酸、山楂酸等),皂苷鞣质、游离酸、脂肪酸、维生素C、无机盐、红色素等。药理作用:所含脂肪酸能促进脂肪消化,并增加胃消化酶的分泌而促进消化,且对胃肠功能有一定调整作用。其提取物能扩张冠状动脉,增加冠脉流量,保护心肌缺血缺氧;并可强心、降血压及抗心律失常;又降血脂,抗动脉粥样硬化,其降低血清胆固醇及甘油三酯,可能是通过提高血清中高密度胆固醇及其亚组分浓度,增加胆固醇的排泄而实现的。另外,山楂还能抗血小板聚集、抗氧化、增强免疫、利尿、镇静、收缩子宫、抑菌等。主要有效成分为各种有机酸类。具有消食健胃、消炎止咳、降血压、降血脂、增进冠状动脉血流量和防治冠心病、心绞痛等作用和抗癌、防癌的功效。降血脂及抗动脉粥样硬化作用北山楂对乳幼大白鼠具明显的降血胆固醇作用。降低率可达30.8%。治疗高甘油三酯血症也有效。南山楂对兔实验性高脂血症有治疗作用,使血清总胆固醇和β脂蛋白降低。北山楂优于南山楂。其降血脂作用,通过对胆固醇合成酶(HMGR)及其分解限速酶7α-羟化酶的研究发现,山楂使豚鼠肝细胞微粒体及小肠粘膜的HMGR活力降低,约降低60%以上,而对肝细胞微粒体7α-羟化酶活性无激动作用。说明主要抑制了胆固醇的合成。山楂对兔实验性动脉粥样硬化有治疗作用,服用以后使血脂下降,眼球上脂质斑块沉着明显减轻,主动脉斑块面积减少,主动脉、冠状动脉病变减轻。山楂对实验性动脉粥样硬化的预防作用与其降低血清总胆固醇和低密度和极低密度脂蛋白胆固醇水平、提高血清高密度Chemicalbook脂蛋白胆固醇水平、尤其是能显著提高HDL2-C水平有关。胆固醇在血浆中大多数以酯化的胆固醇酯形式存在,酯化反应的催化酶即卵磷脂胆固醇酰基转移酶(LCAT),此酶活性降低可造成游离胆固醇的积聚,促进动脉粥样硬化的形成。山楂能有效地提高血清LCAT活性,是其抗动脉粥样硬化的另一种机制。山楂抗动脉粥样硬化作用的有效成分可能是熊果酸。其化学结构与胆固醇相似。另外:山楂核醇提取物能降低高胆固醇症鹌鹑血清TC33.7%~62.8%,(LDL+VLDL)-C降低34.4%~65.6%;并减少胆固醇及胆固醇酯在动脉壁中沉积。其作用随药物剂量的增加而增强。文献报道山楂核具有降低动脉血压,增强心肌收缩力,降血脂,抗心律失常及实验性心肌缺血的作用。山楂叶总黄酮也有类似作用。
桔梗,中药名。为桔梗科桔梗属植物桔梗Platycodon grandiflorus(Jacq.)A.DC.的干燥根。具有宣肺,祛痰,利咽,排脓的功效。主治咳嗽痰多,胸闷不畅,咽喉肿痛,失音,肺痈吐脓。味苦、辛,性平;归肺经。化学成分:本品含多种皂苷,主要为桔梗皂苷,多种混合皂苷经完全水解所产生的皂苷元有桔梗皂苷元,远志酸,以及少量的桔梗酸。另外还含菊糖、植物甾醇等。药理作用:所含的桔梗皂苷对口腔、咽喉部位、胃黏膜的直接刺激,反射性地增加支气管黏膜分泌亢进从而使痰液稀释,易于排出;桔梗有镇咳作用,有增强抗炎和免疫作用,其抗炎强度与阿司匹林相似;水提物能增强巨噬细胞的吞噬功能,增强中性白细胞的杀菌力,提高溶菌酶活性;对应激性溃疡有预防作用。桔梗粗皂苷有镇静、镇痛、解热作用,又能降血糖、降胆固醇,松弛平滑肌。桔梗皂苷有很强的溶血作用,但口服能在消化道中分解破坏而失去溶血作用。降血糖作用正常家免灌服桔梗水或醇提取物200毫克/千克可使血糖下降,与甲苯磺丁脲相似。对实验性四氯嘧啶糖尿Chemicalbook病兔亦有降血糖作用,且能抑制食物性血糖上升,其肝糖元的降低在用药后也见恢复,其中醇提取物作用比水提取物强。
茯苓,中药名。为多孔菌科卧孔属真菌茯苓Poriacocos(Schw.)Wolf的干燥菌核。产云南者称“云苓”,质较优。具有利水消肿,渗湿,健脾,宁心的功效。主治水肿,痰饮,脾虚泄泻,心悸,失眠。味甘、淡,性平;归心、肺、脾、肾经。化学成分:本品含β-茯苓聚糖,占干重约93%,另含茯苓酸、蛋白质、脂肪、卵磷脂、胆碱、组氨酸、麦角甾醇等。
陈皮,中药名。为芸香科柑橘属植物橘Citrus reticulata Blanco及其栽培变种的干燥成熟果皮。具有理气健脾,燥湿化痰的功效。主治脾胃气滞证,呕吐,呃逆,湿痰,寒痰咳嗽,胸痹。味辛、苦,性温;归脾、肺经。化学成分:陈皮中含有川陈皮素、橙皮苷、新橙皮苷、橙皮素、对羟福林、黄酮化合物等。陈皮挥发油含量为1.5%-2.0%,广陈皮挥发油含量为1.2%-3.2%,其成分有α-侧柏烯、柠檬烯等。药理作用:本品煎剂对家兔及小白鼠离体肠管,麻醉兔、犬胃及肠运动均有直接抑制作用;小量煎剂可增强心脏收缩力,使心输出量增加,冠脉扩张,使冠脉流量增加,大剂量时可抑制心脏;陈皮水溶性总生物碱具有升高血压作用;陈皮提取物有清除氧自由基和抗脂质过氧化作用;鲜橘皮煎剂有扩张气管的作用;挥发油有刺激性祛痰作用,主要有效成分为柠檬烯;陈皮煎剂对小鼠离体子宫有抑制作用,高浓度则使之呈完全松弛状态,用煎剂静脉注射,能使麻醉兔在位子宫呈强直性收缩;有利胆、降低血清胆固醇作用。主要含有挥发油、黄酮等活性成分,陈皮提取物能促进体液免疫和细胞免疫,有明显的清除氧自由基作用,起到抗衰老、抗疲劳的作用,Chemicalbook还具有降低胆固醇,抑制试验性溃疡,降低毛细血管通透性,能增强纤维蛋白的溶解,抗血栓形成,具有调节肠胃功能以及利胆等作用。
黄芪,中药名。为豆科黄芪属植物蒙古黄芪Astragalus memeranaceus(Fisch.)Bge.Var.mongholicus(Bge.)Hsiao或膜荚黄芪A.membranaceus(Fisch.)Bge.的根。具有健脾补中,升阳举陷,益卫固表,利尿,托毒生肌的功效。主治脾气虚证,肺气虚证,气虚自汗证,气血亏虚,疮疡难溃难腐,或溃久难敛等。味甘,性微温;归脾、肺经。化学成分:膜荚黄芪根中分离出黄芪苷Ⅰ、黄芪苷Ⅱ、胡萝卜苷、β-谷甾醇、棕榈酸,膜荚黄芪皂苷A、B、C,2',4'-二羟基-5,6-二甲氧基异黄烷、熊竹素、胆碱、甜菜碱、叶酸、毛蕊异黄酮、芒柄花黄素和以三萜环黄芪醇为苷元的黄芪苷Ⅰ、Ⅱ、Ⅲ、Ⅳ。抗菌成分L-3-羟基-9-甲氧基紫檀烷。蒙古黄芪根中含大豆皂苷,黄芪苷Ⅰ、Ⅱ、Ⅳ,胡萝卜苷。含黄芪多糖Ⅰ、Ⅱ、Ⅲ三种均一多糖,并分离出两种葡聚糖AG-1、AG-2和两种杂多糖AH-1、AH-2。AG-1和AH-1具有免疫促进作用。含芒柄花黄素、毛蕊异黄酮等黄酮类化合物;并含天门冬酰胺、刀豆氨酸、脯氨酸、γ-氨基丁酸等21种氨基酸,含有铁、锰、锌、铷等14种微量元素。具有增强免疫力,增强能量,抗疲劳,抗突变,保肝,抑制破骨细胞的作用。黄芪多糖具有降血脂,即降低胆固醇和甘油三酯、升高高密度脂蛋白的作用;能够预防和治疗心脑血管疾病,如动脉粥样硬化、冠状动脉病变、周围血管病变以及高脂血症等。黄芪甲苷具有显著降低血糖、糖化血红蛋白和尿蛋白的作用,可降低肾皮质和血清中的AGEs,显示黄芪甲苷具有抗氧化作用,并对醛糖还原酶有抑制作用,还有抑制系膜细胞增生、减轻肾脏肥大的作用。在黄芪甲苷中加入适当辅料,可制成口服制剂,它用于预防和治疗糖尿病肾病。现代药理研究表明,黄芪具有增强机体免疫功能,强心降压、降血糖、利尿、抗衰老、抗疲劳、抗肿瘤、抗病毒、镇静、镇痛等作用。
江华苦茶,它集苦丁茶与绿茶韵味于一身,与苦丁茶相比,它香气高长,没有苦丁茶的深涩;与绿茶相比,是苦后回甘,滋味浓郁。主要化学成分茶多酚、氨基酸、水浸出物含量三项指标都比较高。具有防治感冒、痢疾之功效,健耳目、舒脾胃的功效。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,水提、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热后,导入氧气进行充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
作为优选地,所述S1中,水提时,固液比为:1:3-5。
作为优选地,所述S1中,水提温度为90-95℃。
作为优选地,所述S2中,加热温度至40-50℃,导入氧气进行2-4h的充氧处理。
与现有技术相比,本发明至少具有如下技术效果:
本发明提供一种降高低密度脂蛋白和高甘油三酯的植物提取液,该植物提取液是以具有药食同源的原料进行组配,进而获得一种能够同时降高低密度脂蛋白和高甘油三酯的产品。该产品兼具有效性和安全性。
该植物提取液的制备方法中,通过水提将山楂、桔梗、茯苓、陈皮和黄芪中的具有降血脂的有效成分析出后,再对江华苦茶原料在一定温度下,导入氧气使提取液中有效成分含氧量提高,进一步保证了江华苦茶原料中有效成分发挥更大的功效。上述各原料提取液混合后,共奏兼具降高低密度脂蛋白和高甘油三酯的作用。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围,实施例中未注明的具体条件,按照常规条件或者制造商建议的条件进行,所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
实施例1:
一种降高低密度脂蛋白和高甘油三酯的植物提取液由以下质量份数的原料制备得到:
山楂提取液100mL,桔梗提取液80mL,茯苓提取液80mL,陈皮提取液50mL,黄芪提取液50mL和江华苦茶提取液50mL。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,90℃下水提(固液比为:1:3)、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热至40℃,导入氧气进行2h充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
实施例2:
一种降高低密度脂蛋白和高甘油三酯的植物提取液由以下质量份数的原料制备得到:
山楂提取液400mL,桔梗提取液300mL,茯苓提取液300mL,陈皮提取液300mL,黄芪提取液300mL和江华苦茶提取液300mL。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,95℃下水提(固液比为:1:5)、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热至50℃,导入氧气进行4h充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
实施例3:
一种降高低密度脂蛋白和高甘油三酯的植物提取液由以下质量份数的原料制备得到:
山楂提取液200mL,桔梗提取液150mL,茯苓提取液150mL,陈皮提取液100mL,黄芪提取液100mL和江华苦茶提取液份100mL。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,90℃下水提(固液比为:1:3)、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热至40℃,导入氧气进行2h充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
实施例4:
一种降高低密度脂蛋白和高甘油三酯的植物提取液由以下质量份数的原料制备得到:
山楂提取液300mL,桔梗提取液200mL,茯苓提取液200mL,陈皮提取液200mL,黄芪提取液200mL和江华苦茶提取液份200mL。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,95℃下水提(固液比为:1:5)、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热至50℃,导入氧气进行4h充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
实施例5:
一种降高低密度脂蛋白和高甘油三酯的植物提取液由以下质量份数的原料制备得到:
山楂提取液230mL,桔梗提取液160mL,茯苓提取液160mL,陈皮提取液130mL,黄芪提取液130mL和江华苦茶提取液130mL。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,95℃下水提(固液比为:1:5)、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热至50℃,导入氧气进行4h充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量0mL数混合,获得成品。
实施例6:
一种降高低密度脂蛋白和高甘油三酯的植物提取液由以下质量份数的原料制备得到:
山楂提取液260mL,桔梗提取液180mL,茯苓提取液180mL,陈皮提取液150mL,黄芪提取液150mL和江华苦茶提取液150mL。
一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,95℃下水提(固液比为:1:5)、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热至50℃,导入氧气进行4h充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
批量20公斤原料为一批次。封装50毫升/支。
具体效果验证如下:
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明的保护范围。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种降高低密度脂蛋白和高甘油三酯的植物提取液,其特征在于,所述植物提取液主要由以下质量份数的原料制备得到:
山楂提取液10-40份,桔梗提取液8-30份,茯苓提取液8-30份,陈皮提取液5-30份,黄芪提取液5-30份和江华苦茶提取液5-30份。
2.根据权利要求1所述的一种降高低密度脂蛋白和高甘油三酯的植物提取液,其特征在于,所述植物提取液主要由以下质量份数的原料制备得到:山楂提取液20-30份,桔梗提取液15-20份,茯苓提取液15-20份,陈皮提取液10-20份,黄芪提取液10-20份和江华苦茶提取液份10-20份。
3.根据权利要求2所述的一种降高低密度脂蛋白和高甘油三酯的植物提取液,其特征在于,所述植物提取液主要由以下质量份数的原料制备得到:山楂提取液23份,桔梗提取液16份,茯苓提取液16份,陈皮提取液13份,黄芪提取液13份和江华苦茶提取液13份。
4.根据权利要求3所述的一种降高低密度脂蛋白和高甘油三酯的植物提取液,其特征在于,所述植物提取液主要由以下质量份数的原料制备得到:山楂提取液26份,桔梗提取液18份,茯苓提取液18份,陈皮提取液15份,黄芪提取液15份和江华苦茶提取液15份。
5.一种根据权利要求1-4任一项所述的降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,其特征在于,包括如下步骤:
S1、分别单独选取山楂、桔梗、茯苓、陈皮和黄芪原料,水提、过滤,分别获得山楂提取液、桔梗提取液、茯苓提取液、陈皮提取液和黄芪提取液备用;
S2、选取江华苦茶原料,加水加热后,导入氧气进行充氧处理,过滤,获得江华苦茶提取液;
S3、将上述各原料提取液按相应的质量份数混合,获得成品。
6.根据权利要求5所述的一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,其特征在于,所述S1中,水提时,固液比为:1:3-5。
7.根据权利要求6所述的一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,其特征在于,所述S1中,水提温度为90-95℃。
8.根据权利要求5所述的一种降高低密度脂蛋白和高甘油三酯的植物提取液的制备方法,其特征在于,所述S2中,加热温度至40-50℃,导入氧气进行2-4h的充氧处理。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310388524.1A CN116370551A (zh) | 2023-04-12 | 2023-04-12 | 一种降高低密度脂蛋白和高甘油三酯的植物提取液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310388524.1A CN116370551A (zh) | 2023-04-12 | 2023-04-12 | 一种降高低密度脂蛋白和高甘油三酯的植物提取液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116370551A true CN116370551A (zh) | 2023-07-04 |
Family
ID=86976662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310388524.1A Pending CN116370551A (zh) | 2023-04-12 | 2023-04-12 | 一种降高低密度脂蛋白和高甘油三酯的植物提取液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116370551A (zh) |
-
2023
- 2023-04-12 CN CN202310388524.1A patent/CN116370551A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101695376B (zh) | 预防糖尿病的保健食品 | |
CN103053748B (zh) | 一种葛根降脂降糖保健茶及其制备方法 | |
CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
CN107648454A (zh) | 一种补肾膏滋及其制备方法 | |
CN102698137A (zh) | 一种具有降低血压作用的组合物及其制备方法 | |
CN104906361A (zh) | 一种降血脂黄酒及其制作方法 | |
CN104208581A (zh) | 一种预防酒精肝的五味子保健口服液及其制备方法 | |
CN106937741A (zh) | 一种脱脂亚麻籽粉防癌抗癌健康减肥法及其制备方法 | |
CN102212449B (zh) | 一种苦荞芽保健酒 | |
CN107751993A (zh) | 一种抗疲劳膏滋及其制备方法 | |
CN105288597A (zh) | 一种治疗皮肤色素沉着的药物 | |
CN108785370A (zh) | 一种用于治疗高血脂症及动脉粥样硬化的药物组合物 | |
CN106085879A (zh) | 一种用药材为培养基培养灵芝综合菌丝体 | |
CN103920011A (zh) | 用于产后肝郁气滞型缺乳的药物组合物及其制备方法 | |
CN116370551A (zh) | 一种降高低密度脂蛋白和高甘油三酯的植物提取液 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
CN102579773A (zh) | 一种补肾壮阳中药片剂、胶囊剂的制备方法 | |
CN112402569A (zh) | 一种抗疲劳保健品及其制备方法 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
CN110522798A (zh) | 一种主治冠心病的复方制剂及其制备方法 | |
CN108929834A (zh) | 铁皮石斛功能性酱香型白酒及其制备方法 | |
CN1234343C (zh) | 降脂洗浴散及其制备方法 | |
CN109123655A (zh) | 一种具有三高人群代餐调节功能的特医食品及制备方法 | |
CN104305179B (zh) | 广谱高效宁心活络降压减脂功能食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |